Kim Stuyckens

The role of naturally occurring and vaccine-induced Ad26 neutralizing antibodies in immunogenicity of Ad26-based vaccines

Mariska G. M. van Rosmalen, Joris Menten, Daniel J Stieh, Nadine Salisch et autres

nl (code pays fourni par la source)

Efficacy and safety of adjunctive treatment with the fatty acid amide hydrolase inhibitor JNJ-42165279 in participants with major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomised study

Mark E. Schmidt, Cynthia Gargano, Xianhuang Zhou, James A. Palmer et autres

us, es (code pays fourni par la source)

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Shubham Pant, Gopa Iyer, Olaf Witt, Shukui Qin et autres

us, de, jp, cn, es, fr, gb, ar, pl, be (code pays fourni par la source)

Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.

Shubham Pant, Martin Schüler, Gopa Iyer, Olaf Witt et autres

us, de, jp, cn, es, fr, gb, ar, be (code pays fourni par la source)

Supplemental Methods, Table 1 and Figures 1-2 from Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients

Xu S. Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith et autres

Data from Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients

Xu S. Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith et autres

Data from Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients

Xu S. Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith et autres

Supplemental Methods, Table 1 and Figures 1-2 from Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients

Xu S. Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith et autres

Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results.

Yohann Loriot, Martin Schüler, Gopa Iyer, Olaf Witt et autres

fr, us, de, jp, cn, es, gb, br (code pays fourni par la source)

Erdafitinib in pediatric patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alterations: RAGNAR study pediatric cohort.

Olaf Witt, Birgit Geoerger, Uta Dirksen, Sameer Farouk Sait et autres

de, fr, us, ar, br, jp (code pays fourni par la source)

A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib

Elena M. Tosca, Nadia Terranova, Kim Stuyckens, Anne‐Gaëlle Dosne et autres

it, ch, be, us (code pays fourni par la source)

Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer

Anne‐Gaëlle Dosne, Elodie Valade, Kim Stuyckens, Peter De Porre et autres

be, us, it (code pays fourni par la source)